DiagnaMed Makes Strides in Molecular Hydrogen Applications
In an exciting move toward advancing treatments for neurological and mental health disorders, DiagnaMed Holdings Corp. has recently filed a provisional patent application with the U.S. Patent and Trademark Office. This application details innovative pharmaceutical methods and compositions aimed at harnessing molecular hydrogen as a potential treatment.
Pioneering Research in Brain Health
The patent application is titled “Methods and Compositions for Producing Hydrogen for Treating Diseases and Disorders Affecting Brain Health.” It reveals a combination of unique pharmaceutical-grade ingredients that could serve as therapeutic options for various neurological conditions, including Dementia, Parkinson’s disease, and Traumatic brain injury, as well as mental health issues, such as Depression, Anxiety, and Post-traumatic stress disorder.
Strategic Plans for Product Development
The foundation of DiagnaMed's strategic initiative aims at partnering with third-party research institutions and life sciences companies. Together, they will work on the manufacturing, clinical research, and commercialization of the company's patent-pending molecular hydrogen product. The company is optimistic that its innovative product will be ready for market in December 2024.
CEO Commentary on Molecular Hydrogen's Potential
Fabio Chianelli, CEO of DiagnaMed, expressed enthusiasm about the advancements, stating, “Molecular hydrogen therapy has promising potential for brain health. We are striving to develop a natural and safe pharmaceutical-grade hydrogen product aimed at tackling neurological and mental health disorders.” The company is now focused on product testing and manufacturing to support clinical research and successful commercialization.
Understanding Molecular Hydrogen and Its Benefits
Molecular hydrogen is widely recognized for its application in various industrial sectors, particularly as a pollution-free fuel. The global market for hydrogen generation reached an estimated size of USD 170.14 billion in 2023, with an expected compound annual growth rate (CAGR) of 9.3% from 2024 through 2030.
Therapeutic Applications of Molecular Hydrogen
As an emerging field, molecular hydrogen therapy is gaining traction, with over 2,000 scientific publications exploring its therapeutic effects through more than 100 human studies. This therapy exhibits promising antioxidant, anti-inflammatory, and neuroprotective properties. It may help manage chronic diseases by reducing oxidative stress and its associated inflammatory pathways. Notably, molecular hydrogen has high cellular bioavailability, offering potential avenues for antiaging protocols and for treating neurodegenerative disorders like Parkinson’s and Alzheimer’s disease.
Research Evidence Supporting Hydrogen Therapy
Research published in reputable journals indicates that hydrogen therapy could have neuroprotective effects for conditions including stroke, neurodegenerative diseases, global brain injury, and trauma. Importantly, clinical studies have reported no adverse effects from hydrogen therapy, which bodes well for its application as an adjunctive treatment for various neurological conditions.
A Cautious Approach to Patented Technologies
While DiagnaMed is enthusiastic about its developments in molecular hydrogen therapy, it emphasizes the need for cautious optimism. The company clarifies that it is not making specific claims regarding the effectiveness of its product in treating neurological and mental health disorders independently or in conjunction with pharmaceuticals. The patent application aims for protection over various methods for producing hydrogen and combining it with ingredients beneficial to brain health.
About DiagnaMed Holdings Corp.
DiagnaMed Holdings Corp. is dedicated to exploring the potential of molecular hydrogen and AI diagnostics to improve brain health. The company also boasts the launch of its innovative BRAIN AGE® Brain Health AI Platform. This world-first consumer-focused solution assesses brain age and provides users with a brain health score, actively promoting awareness and proactive management of brain health.
For further inquiries, reach out to:
Fabio Chianelli
Chairman and CEO
DiagnaMed Holdings Corp.
Tel: 416-800-2684
Email: info@diagnamed.com
Website: www.diagnamed.com
Frequently Asked Questions
What is the main focus of DiagnaMed Holdings Corp.?
DiagnaMed focuses on researching molecular hydrogen and AI diagnostics aimed at improving brain health and addressing neurological and mental health disorders.
What new patent has DiagnaMed filed?
DiagnaMed has filed a provisional patent application for methods and compositions that produce molecular hydrogen as a potential treatment for brain health-related disorders.
When is DiagnaMed's molecular hydrogen product expected to be ready?
The company expects its molecular hydrogen product to be ready for use in December 2024.
What potential benefits does molecular hydrogen offer?
Molecular hydrogen may provide antioxidant effects, reduce inflammation, and protect the brain, making it beneficial for chronic diseases and mental health conditions.
Who can be contacted for more information about DiagnaMed?
Fabio Chianelli, the CEO, can be contacted by phone or via email for more information about the company and its projects.
